Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth

Stock Information for Moving iMage Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Moving iMage Technologies Inc.

Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
Noble Capital Markets Initiates Equity Research Coverage on Zomedica
Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024
Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.